Annuncio • May 26
Nutritional Growth Solutions Ltd. has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Nutritional Growth Solutions Ltd. has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 125,000,000
Price\Range: AUD 0.02
Discount Per Security: AUD 0.0012
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Reported Earnings • Mar 02
Full year 2025 earnings released: US$1.04 loss per share (vs US$0.042 loss in FY 2024) Full year 2025 results: US$1.04 loss per share. Revenue: US$1.63m (down 34% from FY 2024). Net loss: US$1.71m (loss narrowed 41% from FY 2024). Board Change • Jan 05
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Independent Outside Director Rachel Hirsh Kaduri is the most experienced director on the board, commencing their role in 2023. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Annuncio • Dec 24
Nutritional Growth Solutions Ltd. has completed a Follow-on Equity Offering in the amount of AUD 2 million. Nutritional Growth Solutions Ltd. has completed a Follow-on Equity Offering in the amount of AUD 2 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 100,000,000
Price\Range: AUD 0.02
Discount Per Security: AUD 0.0012
Transaction Features: Subsequent Direct Listing Annuncio • Nov 03
Nutritional Growth Solutions Ltd. has filed a Follow-on Equity Offering in the amount of AUD 2 million. Nutritional Growth Solutions Ltd. has filed a Follow-on Equity Offering in the amount of AUD 2 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 100,000,000
Price\Range: AUD 0.02
Discount Per Security: AUD 0.0012
Transaction Features: Subsequent Direct Listing Reported Earnings • Sep 03
First half 2025 earnings released: US$0.016 loss per share (vs US$0.052 loss in 1H 2024) First half 2025 results: US$0.016 loss per share (improved from US$0.052 loss in 1H 2024). Revenue: US$867.0k (down 31% from 1H 2024). Net loss: US$1.18m (loss narrowed 8.3% from 1H 2024). Annuncio • Aug 05
Nutritional Growth Solutions Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.76 million. Nutritional Growth Solutions Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.76 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 38,000,000
Price\Range: AUD 0.02
Discount Per Security: AUD 0.0012
Transaction Features: Subsequent Direct Listing Board Change • Jul 22
High number of new and inexperienced directors There are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Outside Director Rachel Hirsh Kaduri is the most experienced director on the board, commencing their role in 2023. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Annuncio • Jun 30
Nutritional Growth Solutions Ltd. Announces Resignation of Raanan Shamir as Non-Executive Director of the Company Effective 1 July 2025 Nutritional Growth Solutions Ltd. announced that Raanan Shamir has resigned as Non-Executive Director of the Company effective 1 July 2025. The Board wishes to extend its appreciation to Prof. Shamir for his service and contribution to the Company and wishes him all the best with his future endeavors. Annuncio • May 23
Nutritional Growth Solutions Ltd., Annual General Meeting, Jun 30, 2025 Nutritional Growth Solutions Ltd., Annual General Meeting, Jun 30, 2025. Annuncio • Apr 28
Nutritional Growth Solutions Ltd. announced that it expects to receive AUD 1 million in funding Nutritional Growth Solutions Limited has announced that it has entered into binding commitments to issue 1,000,000 convertible notes at a price of AUD 1.00 each for gross proceeds of AUD 1,000,000 on April 28, 2025. The conversion of the convertible notes into ordinary shares in NGS at a price of between AUD 0.03 and AUD 0.025 per ordinary share to occur within 10 business days of NGS shareholders approving their conversion including for the purposes of ASX Listing. Reported Earnings • Apr 05
Full year 2024 earnings released: US$0.042 loss per share (vs US$0.15 loss in FY 2023) Full year 2024 results: US$0.042 loss per share. Revenue: US$2.48m (down 17% from FY 2023). Net loss: US$2.90m (flat on FY 2023). Annuncio • Apr 04
Nutritional Growth Solutions Ltd. Announces CFO Changes On 4 April 2025, Nutritional Growth Solutions Limited announced the appointment of Mr. Manik Pujara as Interim CFO, effective immediately. Mr. Pujara, a Chartered Accountant based in Melbourne and a member of the Australian Institute of Company Directors, has extensive expertise in corporate governance, financial strategy, and change leadership. As a Director at Patison Accountants & Advisors, he has worked closely with businesses to drive growth and enhance operational efficiency. A shareholder in NGS, his alignment with the company's vision underscores his commitment to its success. As part of NGS's ongoing cost-saving initiatives, Mr. Pujara has agreed to receive his compensation in equity. This decision reflects the commitment of the company's leadership, including Directors, the CEO, and the former CFO, who have deferred compensation to support the core team and drive long-term value. Mr. Rob Valerio, who served as Controller since 2019 and as CFO since late 2023, will transition to a supportive role within the finance and accounting team to ensure a smooth handover. Board Change • Feb 28
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Outside Director Guy Khavia was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • Feb 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$1.4m). Earnings have declined by 1.5% per year over the past 5 years. Shareholders have been substantially diluted in the past year (414% increase in shares outstanding). Market cap is less than US$10m (AU$3.88m market cap, or US$2.43m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (US$2.7m revenue). Annuncio • Oct 29
Nutritional Growth Solutions Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.54 million. Nutritional Growth Solutions Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.54 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 18,000,000
Price\Range: AUD 0.03
Discount Per Security: AUD 0.0018
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Annuncio • Oct 23
Nutritional Growth Solutions Ltd. has filed a Follow-on Equity Offering in the amount of AUD 0.54 million. Nutritional Growth Solutions Ltd. has filed a Follow-on Equity Offering in the amount of AUD 0.54 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 18,000,000
Price\Range: AUD 0.03
Discount Per Security: AUD 0.0018
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing New Risk • Jul 25
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Over 5x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (38% average weekly change). Negative equity (-US$177k). Earnings have declined by 14% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (AU$3.26m market cap, or US$2.13m). Minor Risk Revenue is less than US$5m (US$3.0m revenue). Annuncio • Apr 28
Nutritional Growth Solutions Ltd., Annual General Meeting, Jun 25, 2024 Nutritional Growth Solutions Ltd., Annual General Meeting, Jun 25, 2024. Annuncio • Apr 27
Nutritional Growth Solutions Ltd. has filed a Follow-on Equity Offering in the amount of AUD 1.52499 million. Nutritional Growth Solutions Ltd. has filed a Follow-on Equity Offering in the amount of AUD 1.52499 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 508,330,000
Price\Range: AUD 0.003
Discount Per Security: AUD 0.00018
Transaction Features: Subsequent Direct Listing Reported Earnings • Mar 01
Full year 2023 earnings released: US$0.01 loss per share (vs US$0.033 loss in FY 2022) Full year 2023 results: US$0.01 loss per share (improved from US$0.033 loss in FY 2022). Revenue: US$2.98m (up 1.3% from FY 2022). Net loss: US$2.89m (loss narrowed 32% from FY 2022). New Risk • Aug 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.8m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 32% per year over the past 5 years. Shareholders have been substantially diluted in the past year (111% increase in shares outstanding). Market cap is less than US$10m (AU$5.28m market cap, or US$3.43m). Minor Risk Revenue is less than US$5m (US$2.9m revenue). New Risk • Aug 05
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 108% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.8m free cash flow). Earnings have declined by 32% per year over the past 5 years. Shareholders have been substantially diluted in the past year (108% increase in shares outstanding). Market cap is less than US$10m (AU$2.73m market cap, or US$1.79m). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (US$2.9m revenue). Board Change • Aug 01
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Independent Outside Director Guy Khavia was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Annuncio • Jul 25
Nutritional Growth Solutions Ltd. Approves Election of Directors Nutritional Growth Solutions Ltd. at its AGM held on July 25, 2023 approved election of Guy Khavia as an outside Director and Rachel Hirsh as an outside Director. Annuncio • Jun 20
Nutritional Growth Solutions Ltd., Annual General Meeting, Jul 25, 2023 Nutritional Growth Solutions Ltd., Annual General Meeting, Jul 25, 2023, at 14:00 E. Australia Standard Time. Agenda: To consider Re-election of Peter Osborne as Director and approval of Terms of Office; to consider Re-election of Prof Raanan Shamir as Director and approval of Terms of Office; to consider Election of Guy Khavia as an outside Director and approval of Terms of Office; to consider Election of Rachel Hirsh as an outside Director and approval of Terms of Office; to consider ASX Listing Rule 7.1A Approval of Future Issue of Securities; to consider Ratification of Prior Issue of Tranche 1 Placement Share; to consider Approval of Issue of Tranche 2 Placement Shares; and to consider other business matters. Reported Earnings • Feb 25
Full year 2022 earnings released: US$0.03 loss per share (vs US$0.047 loss in FY 2021) Full year 2022 results: US$0.03 loss per share (improved from US$0.047 loss in FY 2021). Revenue: US$2.95m (down 3.1% from FY 2021). Net loss: US$4.25m (loss narrowed 11% from FY 2021). Board Change • Nov 16
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Non-Executive Director Amir Zaidman was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Annuncio • Oct 31
Nutritional Growth Solutions Ltd. Announces Management Changes Nutritional Growth Solutions Ltd. appointed Peter Osborne as Non-executive Director of the board, replacing Dr. Anton Uvarov, who stepped down from the role to pursue other business interests. Mr. Osborne assumed his position as a Strategic Advisor for China and Southeast Asia in May 2022, during which he has provided valuable guidance in commercializing and expanding product ranges into key growth markets across Asia. He is currently a Strategic Advisor in Asia for ASX listed retail and consumer goods companies, Ecofibre Limited and BWX Limited, Director of Advangen, Inc, Japan, Operating Partner of Cortina Capital, Strategic Advisor to Edison Partners, External Advisor to Bain & Company and was previously Asia Pacific Chairman for US probiotic company Seed Health. Annuncio • Oct 19
Nutritional Growth Solutions Ltd. Receives Positive Results from Open Extension Clinical Trial on its Grow Daily Boys 10+ Formula Nutritional Growth Solutions Ltd. has received positive results from open extension (6-12 months) clinical trial on its Grow Daily Boys 10+ formula. Following six months of double-blinded intervention with nutritional formula or placebo, an open-label extension phase was carried out for another six months. In the extension phase Grow Daily Boys 10+ was provided to all the participants in both the intervention and placebo arms. Seventy-nine healthy, lean, and short, pre-adolescent ten to 14.5-year-old males completed the extension phase. The extension phase results found significant dose-response correlations between the consumption of Grow Daily Boys 10+ and the gain in height, weight, and muscle-mass. Throughout the study, net changes in fat mass and fat mass percentage were minor (mean changes of less than 0.8 kg and less than 0.8%, respectively), showing the intervention had no obesogenic effect. Participants who consumed at least 50% of the recommended daily dose of Grow Daily Boys 10+ for either six or 12 months maintained their average height increase rate throughout the year, while poor consumers (who consumed less than 50%) displayed a decrease in growth rate. Highlights: Positive open extension phase (6-12 months) clinical trial results for Healthy Heights® Grow Daily Boys 10+ to assess effect on height, weight, and body composition in healthy, lean, and short pre-adolescent 10 to 14.5-year-old males. Results found significant dose-response correlations between the consumption of Grow Daily Boys 10+ and the gain in height, weight, and muscle-mass. Throughout the study, the net changes in fat mass percentage were minor, supporting the safety of the intervention in terms of a possible obesogenic effect. Participants who consumed at least 50% of the recommended daily dose of Grow Daily Boys 10+ for either 6 or 12 months maintained their average height increase rate throughout the study period, while those who consumed less than 50% displayed a decrease in growth rate. Results of the second six-month phase of a 12-month, randomised, double-blind, placebo-controlled study in peer-reviewed medical journal Hormone Research in Pediatrics 1 Clinical study with a formulation tailored for girls is ongoing. Annuncio • Aug 31
Nutritional Growth Solutions Ltd. Announces Board Changes Nutritional Growth Solutions Ltd. has appointed Peter Osborne as a Non-executive Director on the Board, effective immediately. Based in Taiwan, Mr. Osborne has been a Strategic Advisor to the Company for China and Southeast Asia since May 2022 and will transition to the Board. He will replace Dr Anton Uvarov who will step down effective 31 August 2022 to focus on other business interests. Mr. Osborne was previously Managing Director Asia for Blackmores Limited and has served as Australian Senior Trade Commissioner in Beijing, Shanghai, Hong Kong and Taiwan. He is currently a Strategic Advisor in Asia for ASX listed retail and consumer goods companies, Ecofibre Limited and BWX Limited, Director of Advangen, Inc, Japan, Operating Partner of Cortina Capital, Strategic Advisor to Edison Partners, External Advisor to Bain & Company and was previously Asia Pacific Chairman for US probiotic company Seed Health. Annuncio • Jul 21
Nutritional Growth Solutions Ltd. to Report Q2, 2022 Results on Jul 28, 2022 Nutritional Growth Solutions Ltd. announced that they will report Q2, 2022 results on Jul 28, 2022 Annuncio • Jun 09
Nutritional Growth Solutions Ltd., Annual General Meeting, Jul 14, 2022 Nutritional Growth Solutions Ltd., Annual General Meeting, Jul 14, 2022, at 14:00 W. Australia Standard Time. Agenda: To receive and to consider the Annual Financial Report of the Company for the financial year ended 31 December 2021 consisting of the Independent auditors' statement, consolidated financial statements and notes to the consolidated financial statements; to consider the Re-election of Mr. David Fenlon as Director and Chairman and approval of Terms of Office; to approval of Issue of Options to Mr. David Fenlon (or his Nominee), a director of the company; to consider the ASX Listing Rule 7.1A Approval of Future Issue of Securities; to consider the ratification of Prior Issue of Shares; to consider the appointment of auditor; to consider the adoption of remuneration policy; and to consider the other matters. Annuncio • May 27
Nutritional Growth Solutions Ltd. Appoints Yossi Nizhar as Chief Financial Officer, Effective 1 July 2022 Nutritional Growth Solutions Ltd. announced the appointment of Mr. Yossi Nizhar as Chief Financial Officer (CFO), effective 1 July 2022. Mr. Nizhar joins NGS with more than 20 years' accounting experience in the biotech and international pharmaceutical industries. As a certified public accountant, he served for approximately 10 years as Chief Financial Officer, Israel for AstraZenica, one of the largest global pharmaceutical companies. Most recently,he was CFO for Kadimastem. Mr. Peker will stay in the CFO role until 30 June 2022 to enable an orderly transition. Annuncio • May 18
Nutritional Growth Solutions Ltd. Appoints Strategic Advisors to Accelerate Growth in Australia, China and Southeast Asia Nutritional Growth Solutions Ltd. announced it has appointed two highly experienced strategic advisors for Australia, China and Southeast Asia to maximize growth in these regions. Mr. Peter Osborne has been appointed as a Strategic Advisor for China and Southeast Asia, bringing more than 20 years' industry experience to the role. Mr. Osborne was previously Managing Director Asia for Blackmores Limited and has served as Australian Senior Trade Commissioner in Beijing, Shanghai, Hong Kong and Taiwan. Currently, Mr. Osborne is a Strategic Advisor in Asia for ASX listed retail and consumer goods companies, Ecofibre Limited and BWX Limited, Operating Partner of Cortina Capital, Strategic Advisor to Edison Partners, External Advisor to Bain & Company and Asia Pacific Chairman for US probiotic company Seed Health. Mr. Osborne will work closely with the NGS Board and CEO to grow the Healthy Heights® brand in China and Southeast Asia. In Australia, Mr. Mark Sargent has been appointed as NGS' representative. Mr. Sargent has over 20 years' experience in consumer health, including 18 years at global pharmaceuticals company Bayer where he has been in senior global & Asia Pacific customer & marketing roles and most recently over 10 years as the ANZ General Manager. During this time, Mr. Sargent also was a board member the Australia industry association (Consumer Health Product Australia), including roles as both Chair & Vice Chair. He brings a deep understanding of the Australian consumer health market and will work closely with NGS to position the Company for a successful local launch. Board Change • Apr 27
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Amir Zaidman was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Annuncio • Apr 12
Nutritional Growth Solutions Ltd. Launches Healthy Heights® KidzProtein Nutritional Shakes Nutritional Growth Solutions Ltd. launched Healthy Heights® KidzProtein and KidzProtein Vegan to support children's development. The new product line includes 10 products: KidzProtein comes in chocolate, vanilla, and strawberry; KidzProtein Vegan comes in chocolate and vanilla. Initially launching in the US, the new nutritional shakes [4] which include both dairy and plant-based formulas can serve as a nutritious and delicious breakfast or a healthy tasty snack between meals. They contain a proprietary blend of micro- and macronutrients demonstrated to support optimal childhood growth and development, as well as a fruit and veggie blend. They complement an existing product line shown in a clinical study to help children grow in height and weight. KidzProtein and KidzProtein Vegan provide 10g of protein and a full array of vitamins and minerals. The versatile line allows parents to sneak the added nutrients into smoothies and other recipes. KidzProtein Vegan is a great addition to a child's diet to ensure they are getting enough protein, vitamins, and minerals to fuel their bodies and brains. It contains increased levels of iron, zinc, vitamin B12, and folate to address specific nutritional gaps typically found in vegan diets. KidzProtein Vegan includes pea protein and fava bean protein. In combination, these two proteins contribute allof the essential amino acids, creating a complete protein source. Annuncio • Apr 06
Nutritional Growth Solutions Ltd. Launches Healthy Heights KidzProtein Nutritional Growth Solutions Ltd. launching a Healthy Heights KidzProtein product range to support everyday health in children. The 15 product KidzProtein range will replace NGS' current KidzShake line, with the new nutritional shakes containing a proprietary blend of micro and macro nutrients shown to support optimal childhood growth and development. KidzProtein complements NGS' existing Grow Daily® product lines that are proven in a clinical study to help children grow in height and weight, with no increase in BMI. The KidzProtein range will include both dairy and vegan formulas to support the nutritional needs of the 2 in 10 children with intolerance to dairy-based products in the United States. Reported Earnings • Feb 27
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: US$0.05 loss per share (up from US$0.094 loss in FY 2020). Revenue: US$3.04m (up 63% from FY 2020). Net loss: US$4.78m (loss widened 9.6% from FY 2020). Revenue was in line with analyst estimates. Annuncio • Jan 28
Nutritional Growth Solutions Ltd. to Report Q4, 2021 Results on Jan 31, 2022 Nutritional Growth Solutions Ltd. announced that they will report Q4, 2021 results on Jan 31, 2022 Annuncio • Sep 04
Nutritional Growth Solutions Ltd. Receives Positive Clinical Trial Results for Healthy Heights Grow Daily Boys 10+ Formula Nutritional Growth Solutions Ltd. has received positive results from a clinical trial on its Grow Daily Boys 10+ formula, with the results published in peer-reviewed international pediatric research journal, Acta Paediatrica. The 12-month, randomised, double-blinded, placebo-controlled study was carried out by 160 healthy, lean, and short, pre-adolescent 10 to 14.5-year-old males in two stages: Stage 1 (months 0-6), a double-blinded intervention with nutritional formula or placebo (1:1), and Stage 2 (months 6-12), an open-label extension with the nutritional formula for all the participants. The results found that participants who consumed Grow Daily Boys 10+ over six-months, demonstrated an increase to their weight, BMI, and muscle mass, compared to participants consuming the placebo supplement. Older participants in the study (11.4 years+) who consumed the Grow Daily Boys 10+ formula maintained their height increase rate, while the participants taking the placebo formula displayed a decrease in height increase rate. In addition, the results showed a significant dose-response correlation between the amount of nutritional formula consumed and changes in growth. Annuncio • Aug 31
Nutritional Growth Solutions Ltd. has completed a Follow-on Equity Offering in the amount of AUD 5 million. Nutritional Growth Solutions Ltd. has completed a Follow-on Equity Offering in the amount of AUD 5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 23,255,814
Price\Range: AUD 0.215
Discount Per Security: AUD 0.0129
Transaction Features: Subsequent Direct Listing Annuncio • Aug 25
NGS Launches Grow Daily Boys 10+ Nutritional Shake Nutritional Growth Solutions Ltd. introduced its "Grow Daily Boys 10+" protein drink powder supporting growth and development in boys 10 and older. Launching in the US, the new line contains a patented mixture of macronutrients designed to boost an adolescent's growing body and increase muscle mass. Grow Daily Boys 10+ was formulated with the specific nutritional needs of boys 10 and older in mind. The unique blend incorporates higher levels of macro- and micronutrients needed to support the physical development of young males entering pre-teen and teenage years. Each serving of Grow Daily Boys 10+ contains 18g high-quality whey protein, healthful lipids, and complex carbohydrates, plus micronutrients scientifically proven to be related to growth. These include zinc, calcium, iron, and vitamins A, D, and C. The new line is available in three flavors: Chocolate, Vanilla, and "Plain" (a neutral base) flavor. Grow Daily Boys 10+ Plain is versatile, crafted to be added to milkshakes, fruit smoothies, yogurt, or other delicious recipes. Reported Earnings • Aug 24
First half 2021 earnings released: US$0.02 loss per share (vs US$0.02 loss in 1H 2020) The company reported a mediocre first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: US$1.84m (up 84% from 1H 2020). Net loss: US$2.30m (loss widened 239% from 1H 2020). Annuncio • Jul 07
Nutritional Growth Solutions Ltd. Signs an Agreement for Schneider Children's Medical Centre to Clinically Test Nutritional Growth Solutions Ltd. has signed an agreement for Schneider Children's Medical Centre to clinically test the effectiveness of Healthy Height on the height and weight of children treated with stimulant medications for ADHD (Attention Deficit Hyperactivity Syndrome). Studies report that children treated with stimulants for ADHD may suffer attenuation in height gain both in the short and long term1, which is why an intervention to increase height gain is needed. The randomised, double-blind, placebo-controlled clinical trial will be conducted by the Schneider Children's Medical Centre, the world-renowned specialists in child health and nutrition, where Healthy Height was created.
About 70-140 children under the age of 10 who are currently being treated for ADHD through prescribed stimulant medication will participate in the trial with half of them supplementing their diet with the Healthy Height formula and the other half with a placebo product to determine if nutritional intervention with Healthy Height, increases growth in children treating ADHD with stimulant medication. Attention-deficit hyperactivity disorder (ADHD) is a common behavioral disorder for children. Stimulant use is greatest between 6 and 12 years of age, although use among adolescents is also increasing. Systematic reviews indicate the community prevalence globally is between two and seven per cent, with an average of around 5%. Annuncio • May 19
Nutritional Growth Solutions Ltd. Introduces Healthy Height Snack Bar for Supporting Growth in Children Nutritional Growth Solutions Ltd. introduces its Healthy Height® Snack Bar for supporting growth development in children in the US and Canada. The new, patented, science-based snack-bar line contains growth-boosting nutrients needed to fuel a child's growing body, including vitamins, minerals, protein, and amino acids. The Healthy Height® Snack Bar line comes in two flavors specifically designed to appeal to kids' palates, Cookies & Cream and Strawberry Cupcake. New bar launches for children tracked by Innova Market Insights in the US show a compound annual growth rate of +11.3% (CAGR, 20b16-2020). According to Innova, in response to parents interest, kids cereal bars are increasingly focusing on making gluten-free, protein, and whole-grain claims, representing 50%, 24%, and 24%, respectively, of new product launches. "GMO-free" and "no additives or preservatives" claims are prevalent on cereal bars for kids, globally. Parents increasingly seek products that support specific aspects of children's health, including protein for growth, calcium for strong bones, plus vitamins and probiotics for immunity. The new Healthy Height bars are formulated with the same nutritional profile as the NGS patented shake range that is clinically proven to help increase growth development in children aged 3 to 9 years. It has been shown to help children grow in height and weight with 1-2 servings per day over a six-month period. Each bar is a single serving. (The bars are intended for use as supplemental snacks, and should not be considered as meal replacements.). Annuncio • May 18
Nutritional Growth Solutions Ltd. Signs Binding MoU with NIG Nutritionals to Produce Healthy Height in New Zealand for China and Asia Pacific Markets Nutritional Growth Solutions Ltd. is planning to produce its Healthy Height product in New Zealand for the China and Asia Pacific markets following a binding Memorandum of Understanding (MoU) with dairy-based, nutritional development company, NIG Nutritionals. Under the non-exclusive binding MoU, NIG Nutritionals agrees to manufacture under license, package, and leverage its network to commercialise Healthy Height into China, and possible new markets in the Asia Pacific region. The MoU can be terminated by either party for any reason by giving no less than 60 days' notice. The financial impact of the MoU is not determinable at this time, with revenue generated by the company subject to customer purchases of its products. This partnership establishes a high-quality production base for Healthy Height in the Asia Pacific market that provides cost, production and distribution efficiency into China and the wider Asia Pacific region. Reported Earnings • Mar 31
Full year 2020 earnings released: US$0.094 loss per share (vs US$0.056 loss in FY 2019) The company reported a mediocre full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: US$1.87m (up 58% from FY 2019). Net loss: US$4.36m (loss widened 115% from FY 2019). Annuncio • Mar 09
Nutritional Growth Solutions Ltd. to Launch Its Patented Healthy Height Product in the EU Nutritional Growth Solutions Ltd. has announced it will launch its patented Healthy Height product in the EU through a 3 years exclusive distribution agreement with clinically tested product distributor, Dicofarm. Developed over 20 years by leading pediatric specialists from the world-renowned Schneider Children's Medical Center in Israel, Healthy Height® is a scientifically formulated nutritional product clinically proven to assist children grow taller through shakes and foods that contain specific key nutrients needed for growth. Under the exclusive distribution agreement Dicofarm will initially have Healthy Height available for purchase in pharmacies and health food stores throughout Italy - a country with 8.2 million children under 14 years of age. Healthy Height is sold in Italy under the name "Dico Up". The financial impact of the Agreement is not determinable at this time, with revenue generated by the Company subject to customer purchases of its products. Is New 90 Day High Low • Feb 26
New 90-day low: AU$0.23 The company is down 29% from its price of AU$0.33 on 27 November 2020. The Australian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 7.0% over the same period. Annuncio • Jan 21
Nutritional Growth Solutions Ltd. Expanding US Reach with its Kids' Nutritional Shakes Nutritional Growth Solutions Ltd. completed an agreement to bring its pediatric nutritional height-boosting solution, Healthy Height®, to the US medical market. NGS signed a vendor agreement with a leading US medical distributor, Independent Medical Co-op Inc. (IMCO) for the US distribution of Healthy Height, its patented protein shake clinically shown to improve children's height. The agreement gives NGS access to IMCO's broad healthcare network, encompassing homecare and independent pharmacies throughout the US. Under the agreement, NGS will leverage IMCO's sales, marketing, and logistical platforms while the two entities initiate a joint campaign to drive product awareness among IMCO's member network. Healthy Height was developed and tested by pediatricians as a holistic solution to nourish growing children aged three to nine years. It also helps support nutrition in picky eaters, a universal problem that brings a lot of stress to families. Healthy Height is well established in the US market as a leading complementary solution supporting growth for kids. It contains 12g whey protein per serving, plus other high-value ingredients, and no additives. It is gluten-free, soy-free, contains no GMO's, and includes 350mg of the essential amino acid arginine per serving. It also is low in sugar and sodium. Annuncio • Jan 08
Nutritional Growth Solutions Ltd. Launches Online Store in China Nutritional Growth Solutions Ltd. announced the launch of Healthy Height store on Tmall Global, Alibaba's B2C online platform for international brands and retailers, to introduce its products to more than half a billion consumers on Alibaba's platform in China. The new Healthy Height Tmall Global store gives Chinese consumers access to Healthy Height's clinically tested protein shakes for children, reflecting increasing demand for high- quality, and international nutrition brands in China. The severity of the COVID19 pandemic has encouraged the general population of China to reconsider their dietary habits. This has resulted in a significant rise in popularity for Health Supplement products on both online and offline sales channels. Increasing per-capita disposable income also allows Chinese consumers to pay more attention towards premium foreign brands. As a result, nutritional supplements were among the growing categories on Tmall Global during 2020 with monthly sales exceeding 1B RMB (approx. 200m AUD) with protein powders/amino acids among the categories. 